Trials / Recruiting
RecruitingNCT07327840
Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)
A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of Kylo-11 in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 204 (estimated)
- Sponsor
- Kylonova (Xiamen) Biopharma co., LTD. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2, double-blind, randomized, placebo-controlled, multi-center, dose-finding study to evaluate the efficacy and safety of Kylo-11 administered subcutaneously compared to placebo in participants with ASCVD and elevated Lp(a).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Kylo-11 or matched placebo | Administered subcutaneously |
Timeline
- Start date
- 2025-10-29
- Primary completion
- 2027-02-28
- Completion
- 2028-08-31
- First posted
- 2026-01-08
- Last updated
- 2026-03-23
Locations
43 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07327840. Inclusion in this directory is not an endorsement.